Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 14, 2022 08:30 ET | Source: Scynexis

SCYNEXIS to Present Data from the CANDLE Nested Sub-Study of Ibrexafungerp During the International Society for the Study of Vulvovaginal Disease (ISSVD) XXVI World Congress and International Vulvovaginal Disease Update

JERSEY CITY, N.J., July 14, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
June 23, 2022 08:30 ET | Source: Scynexis

SCYNEXIS Announces Initiation of New Phase 3b Study (VANQUISH) to Evaluate Oral Ibrexafungerp as a Treatment for Complicated Vulvovaginal Candidiasis (VVC) in Patients Who Failed to Respond to Treatment with Fluconazole

JERSEY CITY, N.J., June 23, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
June 08, 2022 08:30 ET | Source: Scynexis

SCYNEXIS Announces Submission of Supplemental New Drug Application of BREXAFEMME® (ibrexafungerp tablets) to the U.S. Food and Drug Administration for an Expanded Indication for the Prevention of Recurrent Vaginal Yeast Infections

Regulatory submission for the label extension is supported by positive data from the pivotal Phase 3 CANDLE study in which ibrexafungerp successfully achieved statistically significant superiority...
June 03, 2022 16:05 ET | Source: Scynexis

SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

JERSEY CITY, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
May 20, 2022 08:30 ET | Source: Scynexis

SCYNEXIS to Present at Upcoming H.C. Wainwright Global Investment Conference

JERSEY CITY, N.J., May 20, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
May 12, 2022 07:00 ET | Source: Scynexis

SCYNEXIS Reports First Quarter 2022 Financial Results and Provides Corporate Update

BREXAFEMME® (ibrexafungerp tablets), launched in September 2021 for the treatment of vulvovaginal candidiasis (VVC), achieved almost 4,000 prescriptions with net revenues of $0.7 million in Q1 2022....
May 10, 2022 08:30 ET | Source: Scynexis

SCYNEXIS Presents New Interim Positive Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting

Data show that of the FURI study patients with refractory or relapsed vulvovaginal candidiasis (VVC) treated with ibrexafungerp, 71.4% had successful clinical outcomes. Ibrexafungerp demonstrated...
May 05, 2022 08:30 ET | Source: Scynexis

SCYNEXIS to Report First Quarter 2022 Financial Results and Provide a Corporate Update on May 12

JERSEY CITY, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
May 04, 2022 08:30 ET | Source: Scynexis

SCYNEXIS to Present New Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting

JERSEY CITY, N.J., May 04, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
April 27, 2022 08:30 ET | Source: Scynexis

SCYNEXIS Presents Data Analyses Showing Ibrexafungerp’s Potential to Fight Invasive Candidiasis and Candidemia, Including Infections Caused by Candida Auris, During the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases

New interim analysis of the Phase 3 CARES study showed complete or partial response in 78% of the 18 patients treated with ibrexafungerp for infections caused by Candida auris, a potentially deadly...